Global Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Research Report 2025

Publication ID:

PB503254484

Publication Date:

March 4, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Acute Myeloid Leukemia (AML) Biomarker Testing was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Acute Myeloid Leukemia (AML) biomarker testing is a diagnostic and prognostic approach that involves the analysis of specific biological markers or genetic alterations in the cells of a patient with AML, a type of blood cancer that affects the bone marrow and blood. Biomarkers in AML testing are used to help diagnose the disease, classify subtypes, guide treatment decisions, and assess the prognosis of AML patients. These markers can be found in the AML cells themselves or in the surrounding bone marrow environment.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents鈥� wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia (AML) Biomarker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia (AML) Biomarker Testing.
The Acute Myeloid Leukemia (AML) Biomarker Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Acute Myeloid Leukemia (AML) Biomarker Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Myeloid Leukemia (AML) Biomarker Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Abbott Laboratories
Novartis AG
Thermo Fisher Scientific
Cancer Genetics Inc.
Sysmex Corporation
Epigenomics AG
BioMerieux SA
Skyline DX B.V.
Segment by Type
Genetic Acute Myeloid Leukemia (AML) Biomarker
Epigenetic Acute Myeloid Leukemia (AML) Biomarker
Proteomic Acute Myeloid Leukemia (AML) Biomarker
Segment by Application
Hospitals
Cancer diagnostic Centers
Research Institutes
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Myeloid Leukemia (AML) Biomarker Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Genetic Acute Myeloid Leukemia (AML) Biomarker
1.2.3 Epigenetic Acute Myeloid Leukemia (AML) Biomarker
1.2.4 Proteomic Acute Myeloid Leukemia (AML) Biomarker
1.3 麻豆原创 by Application
1.3.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Cancer diagnostic Centers
1.3.4 Research Institutes
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Perspective (2020-2031)
2.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Growth Trends by Region
2.2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Acute Myeloid Leukemia (AML) Biomarker Testing Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Dynamics
2.3.1 Acute Myeloid Leukemia (AML) Biomarker Testing Industry Trends
2.3.2 Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Drivers
2.3.3 Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Challenges
2.3.4 Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Revenue
3.1.1 Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Revenue (2020-2025)
3.1.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue
3.4 Global Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Concentration Ratio
3.4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in 2024
3.5 Global Key Players of Acute Myeloid Leukemia (AML) Biomarker Testing Head office and Area Served
3.6 Global Key Players of Acute Myeloid Leukemia (AML) Biomarker Testing, Product and Application
3.7 Global Key Players of Acute Myeloid Leukemia (AML) Biomarker Testing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Myeloid Leukemia (AML) Biomarker Testing Breakdown Data by Type
4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted 麻豆原创 Size by Type (2026-2031)
5 Acute Myeloid Leukemia (AML) Biomarker Testing Breakdown Data by Application
5.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size (2020-2031)
6.2 North America Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size by Country (2020-2025)
6.4 North America Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size (2020-2031)
7.2 Europe Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size by Country (2020-2025)
7.4 Europe Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size (2020-2031)
9.2 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.1.4 Abbott Laboratories Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.1.5 Abbott Laboratories Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.2.4 Novartis AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.2.5 Novartis AG Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Details
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.3.4 Thermo Fisher Scientific Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Cancer Genetics Inc.
11.4.1 Cancer Genetics Inc. Company Details
11.4.2 Cancer Genetics Inc. Business Overview
11.4.3 Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.4.4 Cancer Genetics Inc. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.4.5 Cancer Genetics Inc. Recent Development
11.5 Sysmex Corporation
11.5.1 Sysmex Corporation Company Details
11.5.2 Sysmex Corporation Business Overview
11.5.3 Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.5.4 Sysmex Corporation Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.5.5 Sysmex Corporation Recent Development
11.6 Epigenomics AG
11.6.1 Epigenomics AG Company Details
11.6.2 Epigenomics AG Business Overview
11.6.3 Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.6.4 Epigenomics AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.6.5 Epigenomics AG Recent Development
11.7 BioMerieux SA
11.7.1 BioMerieux SA Company Details
11.7.2 BioMerieux SA Business Overview
11.7.3 BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.7.4 BioMerieux SA Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.7.5 BioMerieux SA Recent Development
11.8 Skyline DX B.V.
11.8.1 Skyline DX B.V. Company Details
11.8.2 Skyline DX B.V. Business Overview
11.8.3 Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.8.4 Skyline DX B.V. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2020-2025)
11.8.5 Skyline DX B.V. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Abbott Laboratories
Novartis AG
Thermo Fisher Scientific
Cancer Genetics Inc.
Sysmex Corporation
Epigenomics AG
BioMerieux SA
Skyline DX B.V.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.